Vilacto Bio, Inc. (OTC QB: VIBI) is a biotechnology company that developed the LACTOACTIVE® skin therapy, which helps treat a variety of medical issues, including diabetes and skin aging. Shares surged 48.35% during trading on November 30, 2018. Over the past month, Vilacto Bio has seen an average daily volume of 65,393 shares. However, volume of 355,057 shares or dollar volume of $47,932, exchanged hands during Friday’s trading.
Shares surged Friday morning after Vilacto Bio, Inc. announced it has secured the patent applications for LACTOACTIVE® covering rights in the US, Canada, Europe, and Hong Kong. Vilacto Bio has been licensing the US rights from a Danish company but now with the ownership of the patent application, they will be able to continue developing Lactoactive and bolster its international IP ownership position. The patent applications will also cover LACTOACTIVE iTHER®, a newly-developed LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. CEO Gert Anderson said, “Vilacto Bio now is in a stronger position than ever to leverage the potential of LACTOACTIVE iTHER® for immunotherapy and vaccine-based treatments.” Here is the full press release detailing the patent applications:
Vilacto Bio Inc. Press Release:
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) — New York-based Vilacto Bio Inc. (OTC QB:VIBI) has secured the patent applications for LACTOACTIVE® covering rights in the US, Canada Europe and Hong Kong. The transaction was finalized this November.
Ownership of the patent applications, which Vilacto Bio had been licensing the US rights from a Danish company, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound, and bolster its international IP ownership position.
The patent applications also cover the company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. LACTOACTIVE iTHER® is expected to generate new revenue streams in addition to the company’s LACTOACTIVE®-based therapeutic skincare range.
“Vilacto Bio now is in a stronger position than ever to leverage the potential of LACTOACTIVE iTHER® for immunotherapy and vaccine-based treatments,” said Vilacto Bio CEO Gert Anderson.
“Our research shows that LACTOACTIVE iTHER® can contribute significantly to emerging therapies for treating diseases such as cancer, immunodeficiency disorders, osteoarthritis, psoriasis and thrombocytopenia.”
The main active component of LACTOACTIVE® and LACTOACTIVE iTHER® is colostrum, a natural substance that Vilacto Bio has refined and processed into a potent nanoparticle concentrate. In NPDDS form, the compound can be applied in deeper layers of the skin and, when injected, can penetrate cell walls to act directly on cytoplasm. The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.
Vilacto Bio plans to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Article By: Andrew Rego